Innate Pharma SA (FR:IPH) has released an update.
Innate Pharma SA, a clinical-stage biotechnology company, has disclosed its total number of shares and voting rights as of July 10, 2024. The company, known for developing innovative immunotherapies for cancer patients, reported a total of 80,969,357 ordinary shares and a mix of preferred shares, leading to a total of 81,724,597 theoretical voting rights. Headquartered in Marseille, France, Innate Pharma is listed on both Euronext Paris and the Nasdaq, focusing on proprietary programs such as lacutamab and partnerships with industry leaders like AstraZeneca.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.